The second group of viral antigen-based techniques consists of commercially available immunoassays, commonly referred to as RADTs. Compared with IF, the principle of RSV RADTs is similar in that a ...

This review seeks to familiarize the readers with RSV rapid antigen-detection tests, describe their performance characteristics and comment on their strengths and weaknesses. The authors will ...

Trial met primary endpoint, non-inferior immune response for both vaccines when co-administered compared with separate ...

The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...

According to the province's monthly respiratory illness surveillance report, COVID-19 and influenza have increased slightly ...

Pfizer recently terminated the development of its Phase 2 respiratory vaccine combination PF-07960613, designed to protect against RSV and COVID ... on its mRNA-shared antigen melanoma vaccine ...

identified a protein in RSV a decade ago that looked like a promising antigen for vaccine development. Both Arexvy and Abrysvo target this PreF protein, as do other candidates in the late-stage ...

RSV F is a class 1 fusion protein and undergoes a dramatic refolding to mediate virus entry. The prefusion form of F was found to be a much better vaccine antigen than the rearranged postfusion ...

BEYFORTUS is not an RSV vaccine but offers passive immunization ... peptides), and nucleic acids (RNA and DNA) encoding the antigen(s) of interest. No fungal vaccine has been approved as of 2024.

Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, hospitalizations, lost quality of life, and deaths, according to one study.